Novel Compounds for Fibrosis Treatment and Tissue Restoration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fibrosis lack effective agents to prevent, reduce, or slow the progression of fibrosis, particularly in organs like the heart, kidney, and liver, where fibrotic changes lead to tissue scarring and organ dysfunction, with a need for compounds that can address renal tubular cell death and fat accumulation in the liver.
Innovation Solution
Development of novel compounds represented by specific formulae, including substituted heterocyclyl, alkoxyl amine, alkyl amine, alkyl carboxylic acid, and alkyl hydroxyl groups, or their pharmacologically acceptable salts, which are administered to prevent, reduce, or slow fibrosis progression, restore tissue architecture, and address renal tubular cell death and liver fat accumulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for fibrosis, then existing therapeutic options are limited, but effective prevention and treatment of fibrosis progression is not achieved
Solution Approach 1:
The patent applies parameter changes by developing novel chemical compounds with specific molecular structures (formula 1) that differ from existing treatments. The compounds feature variable substituents (R1-R6) and heterocyclic groups (A) that can be modified to optimize anti-fibrotic activity, thereby improving treatment effectiveness while expanding therapeutic options.
Solution Approach 2:
The invention employs composite materials principles by creating compounds that combine multiple functional groups (heterocyclyl, alkoxyl amine, alkyl amine, alkyl carboxylic acid, alkyl hydroxyl) into a single molecular structure. This composite approach enables the compound to address multiple aspects of fibrosis pathogenesis simultaneously, enhancing overall treatment efficacy.
2Reliability
If fibrotic changes progress unchecked, then tissue scarring and organ dysfunction occur, but early intervention with effective agents is lacking
Solution Approach 1:
The patent implements preliminary action by developing compounds capable of preventing fibrosis at early stages before irreversible tissue scarring occurs. The compounds target early fibrotic pathways and can be administered before significant organ dysfunction develops, thereby preventing tissue scarring and preserving organ function.
Solution Approach 2:
The invention applies preliminary anti-action by creating compounds that counteract fibrotic processes before they lead to severe tissue damage. The compounds inhibit fibrosis progression and can reverse early fibrotic changes, preventing the loss of time associated with unchecked fibrotic progression.
3Reliability
If specific organ fibrosis is treated, then renal tubular cell death and liver fat accumulation are not adequately addressed
Solution Approach 1:
The patent applies universality by developing compounds with broad multi-organ protective effects. The compounds demonstrate activity against fibrosis in multiple organs including kidney (preventing tubular cell death) and liver (reducing fat accumulation), thereby providing comprehensive organ protection and addressing diverse fibrotic conditions with a single therapeutic agent.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of fibrosis and fibrosis-related conditions.